Lilly may boost biotech business through follow-on biologics

12/11/2008 | Reuters · Wall Street Journal, The

Eli Lilly and Co. CEO John Lechleiter said the company is "very much considering" developing follow-on biologics but clarified that the firm has yet to include such products in its pipeline. The drugmaker "could do particularly well" in such a venture because of its protein-engineering capabilities, said Steven Paul, president of Lilly Research Laboratories.

View Full Article in:

Reuters · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ